The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Small Molecule Drug CDMO Market Research Report 2024
Synopsis
A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
Global Small Molecule Drug CDMO market is projected to reach US$ 41580 million in 2029, increasing from US$ 27840 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Small Molecule Drug CDMO market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Small Molecule Drug CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Segment by Type
FDF CDMO
Packaging CDMO
Clinical CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Small Molecule Drug CDMO report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
Global Small Molecule Drug CDMO market is projected to reach US$ 41580 million in 2029, increasing from US$ 27840 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Small Molecule Drug CDMO market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Small Molecule Drug CDMO market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Segment by Type
FDF CDMO
Packaging CDMO
Clinical CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Small Molecule Drug CDMO report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Small Molecule Drug CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 FDF CDMO
1.2.3 Packaging CDMO
1.2.4 Clinical CDMO
1.3 Market by Application
1.3.1 Global Small Molecule Drug CDMO Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Small Molecule Drug CDMO Market Perspective (2018-2029)
2.2 Small Molecule Drug CDMO Growth Trends by Region
2.2.1 Global Small Molecule Drug CDMO Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Small Molecule Drug CDMO Historic Market Size by Region (2018-2023)
2.2.3 Small Molecule Drug CDMO Forecasted Market Size by Region (2024-2029)
2.3 Small Molecule Drug CDMO Market Dynamics
2.3.1 Small Molecule Drug CDMO Industry Trends
2.3.2 Small Molecule Drug CDMO Market Drivers
2.3.3 Small Molecule Drug CDMO Market Challenges
2.3.4 Small Molecule Drug CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Small Molecule Drug CDMO Players by Revenue
3.1.1 Global Top Small Molecule Drug CDMO Players by Revenue (2018-2023)
3.1.2 Global Small Molecule Drug CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Small Molecule Drug CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Small Molecule Drug CDMO Revenue
3.4 Global Small Molecule Drug CDMO Market Concentration Ratio
3.4.1 Global Small Molecule Drug CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Small Molecule Drug CDMO Revenue in 2022
3.5 Small Molecule Drug CDMO Key Players Head office and Area Served
3.6 Key Players Small Molecule Drug CDMO Product Solution and Service
3.7 Date of Enter into Small Molecule Drug CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Small Molecule Drug CDMO Breakdown Data by Type
4.1 Global Small Molecule Drug CDMO Historic Market Size by Type (2018-2023)
4.2 Global Small Molecule Drug CDMO Forecasted Market Size by Type (2024-2029)
5 Small Molecule Drug CDMO Breakdown Data by Application
5.1 Global Small Molecule Drug CDMO Historic Market Size by Application (2018-2023)
5.2 Global Small Molecule Drug CDMO Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Small Molecule Drug CDMO Market Size (2018-2029)
6.2 North America Small Molecule Drug CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Small Molecule Drug CDMO Market Size by Country (2018-2023)
6.4 North America Small Molecule Drug CDMO Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Small Molecule Drug CDMO Market Size (2018-2029)
7.2 Europe Small Molecule Drug CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Small Molecule Drug CDMO Market Size by Country (2018-2023)
7.4 Europe Small Molecule Drug CDMO Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Small Molecule Drug CDMO Market Size (2018-2029)
8.2 Asia-Pacific Small Molecule Drug CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Small Molecule Drug CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific Small Molecule Drug CDMO Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Small Molecule Drug CDMO Market Size (2018-2029)
9.2 Latin America Small Molecule Drug CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Small Molecule Drug CDMO Market Size by Country (2018-2023)
9.4 Latin America Small Molecule Drug CDMO Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Small Molecule Drug CDMO Market Size (2018-2029)
10.2 Middle East & Africa Small Molecule Drug CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Small Molecule Drug CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa Small Molecule Drug CDMO Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Detail
11.1.2 Lonza Business Overview
11.1.3 Lonza Small Molecule Drug CDMO Introduction
11.1.4 Lonza Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Detail
11.2.2 Catalent Business Overview
11.2.3 Catalent Small Molecule Drug CDMO Introduction
11.2.4 Catalent Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.2.5 Catalent Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Detail
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Small Molecule Drug CDMO Introduction
11.3.4 Thermo Fisher Scientific Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Detail
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Small Molecule Drug CDMO Introduction
11.4.4 Samsung Biologics Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.4.5 Samsung Biologics Recent Development
11.5 Fareva
11.5.1 Fareva Company Detail
11.5.2 Fareva Business Overview
11.5.3 Fareva Small Molecule Drug CDMO Introduction
11.5.4 Fareva Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.5.5 Fareva Recent Development
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Detail
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Small Molecule Drug CDMO Introduction
11.6.4 WuXi AppTech Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.6.5 WuXi AppTech Recent Development
11.7 WuXi Biologics
11.7.1 WuXi Biologics Company Detail
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Small Molecule Drug CDMO Introduction
11.7.4 WuXi Biologics Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.7.5 WuXi Biologics Recent Development
11.8 Siegfried
11.8.1 Siegfried Company Detail
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Small Molecule Drug CDMO Introduction
11.8.4 Siegfried Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.8.5 Siegfried Recent Development
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Small Molecule Drug CDMO Introduction
11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.10 Asymchem
11.10.1 Asymchem Company Detail
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Small Molecule Drug CDMO Introduction
11.10.4 Asymchem Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.10.5 Asymchem Recent Development
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Company Detail
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Small Molecule Drug CDMO Introduction
11.11.4 Pfizer CentreOne Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.11.5 Pfizer CentreOne Recent Development
11.12 Delpharm
11.12.1 Delpharm Company Detail
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Small Molecule Drug CDMO Introduction
11.12.4 Delpharm Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.12.5 Delpharm Recent Development
11.13 Recipharm
11.13.1 Recipharm Company Detail
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Small Molecule Drug CDMO Introduction
11.13.4 Recipharm Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.13.5 Recipharm Recent Development
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Company Detail
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Small Molecule Drug CDMO Introduction
11.14.4 AGC Pharma Chemicals Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.14.5 AGC Pharma Chemicals Recent Development
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Detail
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Small Molecule Drug CDMO Introduction
11.15.4 Boehringer Ingelheim Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.15.5 Boehringer Ingelheim Recent Development
11.16 Vetter
11.16.1 Vetter Company Detail
11.16.2 Vetter Business Overview
11.16.3 Vetter Small Molecule Drug CDMO Introduction
11.16.4 Vetter Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.16.5 Vetter Recent Development
11.17 Curia
11.17.1 Curia Company Detail
11.17.2 Curia Business Overview
11.17.3 Curia Small Molecule Drug CDMO Introduction
11.17.4 Curia Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.17.5 Curia Recent Development
11.18 Aenova
11.18.1 Aenova Company Detail
11.18.2 Aenova Business Overview
11.18.3 Aenova Small Molecule Drug CDMO Introduction
11.18.4 Aenova Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.18.5 Aenova Recent Development
11.19 Porton
11.19.1 Porton Company Detail
11.19.2 Porton Business Overview
11.19.3 Porton Small Molecule Drug CDMO Introduction
11.19.4 Porton Revenue in Small Molecule Drug CDMO Business (2018-2023)
11.19.5 Porton Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
